The kidney contains ontogenetically distinct dendritic cell and macrophage subtypes throughout development that differ in their inflammatory properties
LEADER trial showed that 32.2% patients experienced severe AEs in the liraglutide group for 4.5 years follow-up period, while these AE not only limited to gastrointestinal ( Although our study had significant advantages based on the FAERS database and data mining technology, there were also some limitations inherent to its observational design
Other common gastrointestinal side effects include: Diarrhoea loose or frequent bowel movements affecting 20-30% of patients Constipation paradoxically, some patients experience reduced bowel frequency Abdominal pain or discomfort cramping or generalised abdominal discomfort Dyspepsia indigestion, bloating, or upper abdominal fullness Decreased appetite whilst this is part of the therapeutic effect, it can feel uncomfortable Beyond gastrointestinal symptoms, patients may experience other effects that contribute to feeling unwell
Very satisfied works as intended
It is VERY IMPORTANT to be under the care of an Close monitoring protocols of your progress, your response, any side effects or changes in treatment plan are set forth by the physician
However, its important to note that these studies were conducted at concentrations that greatly exceed the maximum human dose